Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 5/20 | 0.39 |
| ▸ | RAB9A | P51151 | 5/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.38 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.37 |
| ▸ | WNT3A | P56704 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6182003 | 0.86 | AOC3 (0.42) | ALDH1A1HPGDHTTNPC1RAB9A | |
| SCHEMBL7809964 | 0.84 | KDM4E (0.53) | KDM4EALDH1A1HSD17B10HPGDHTT | |
| SCHEMBL2427488 | 0.84 | KDM4E (0.55) | KDM4EALDH1A1HSD17B10HPGDHTT | |
| SCHEMBL17424960 | 0.83 | KDM4E (0.47) | KDM4EALDH1A1HSD17B10HPGDHTT | |
| SCHEMBL668435 | 0.82 | KDM4E (0.43) | KDM4EALDH1A1HSD17B10HPGDHTT | |
| SCHEMBL20563025 | 0.80 | KDM4E (0.50) | KDM4EALDH1A1HSD17B10HPGDHTT | |
| SCHEMBL17424932 | 0.80 | BAZ2B (0.49) | KDM4EALDH1A1HSD17B10HPGDHTT | |
| SCHEMBL6184313 | 0.79 | KDM4E (0.38) | KDM4EALDH1A1HSD17B10HPGDHTT | |
| SCHEMBL668928 | 0.79 | ATM (0.40) | KDM4EALDH1A1HSD17B10HPGDHTT | |
| SCHEMBL7478893 | 0.76 | CTNNB1 (0.40) | ALDH1A1ADRA2AADRA2CNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0639559-B1 | Preparation of 1,2-diacyl-2-(t-alkyl)hydrazines | ROHM & HAAS (US) | 1997-10-15 | — | — | EP | claimed |
| EP-0639559-A1 | Preparation of 1,2-diacyl-2-(t-alkyl)hydrazines | ROHM AND HAAS COMPANY (US) | 1995-02-22 | — | — | EP | claimed |
| EP-1601642-B1 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2017-01-04 | — | — | EP | disclosed |
| EP-1601642-B1 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2017-01-04 | — | — | EP | disclosed |
| EP-2463269-B1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORP (US) | 2016-09-28 | — | — | EP | disclosed |
| US-9359289-B2 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2016-06-07 | — | — | US | disclosed |
| US-9359289-B2 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2016-06-07 | — | — | US | disclosed |
| US-9359289-B2 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2016-06-07 | — | — | US | disclosed |
| US-20160039750-A1 | Bioavailable Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | INTREXON CORPORATION (US) | 2016-02-11 | — | — | US | disclosed |
| US-9255273-B2 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2016-02-09 | — | — | US | disclosed |
| US-9255273-B2 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2016-02-09 | — | — | US | disclosed |
| EP-0639559-B1 | Preparation of 1,2-diacyl-2-(t-alkyl)hydrazines | ROHM & HAAS (US) | 1997-10-15 | — | — | EP | disclosed |
| US-5672723-A | SELECTIVE HYDROLYSIS OR ALCOHOLYSIS OF A MIXTURE OF 1-ACYL-1-ALKYLHYDRAZINE AND 1-ACYL-2-ALKYLHYDRAZINE USING AN ACID CATALYST TO OBTAIN AN ACID OR ESTER AND THE STABLE 1-ACYL-2-ALKYLHYRAZINE | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1997-09-30 | — | — | US | disclosed |
| EP-0496342-B1 | New hydrazine derivative and pesticidal composition comprising said derivative as an effective ingredient | NIPPON KAYAKU KK (JP) | 1996-11-27 | — | — | EP | disclosed |
| EP-0639558-B1 | Process for preparation of 1-acyl-2-substituted-hydrazines | NIPPON KAYAKU KK (JP) | 1996-10-23 | — | — | EP | disclosed |
| US-5530021-A | AGRICULTURAL INSECTICIDES | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1996-06-25 | — | — | US | disclosed |
| EP-0639559-A1 | Preparation of 1,2-diacyl-2-(t-alkyl)hydrazines | ROHM AND HAAS COMPANY (US) | 1995-02-22 | — | — | EP | disclosed |
| EP-0639558-A1 | Process for preparation of 1-acyl-2-substituted-hydrazines | Nippon Kayaku Kabushiki Kaisha (JP) | 1995-02-22 | — | — | EP | disclosed |
| US-5378726-A | Insecticide, parasiticide | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1995-01-03 | — | — | US | disclosed |
| EP-0496342-A1 | New hydrazine derivative and pesticidal composition comprising said derivative as an effective ingredient | Nippon Kayaku Kabushiki Kaisha (JP) | 1992-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039750-A1 | Bioavailable Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | NR2E3, NR5A1, NR5A2 | KDM4E 3652/4885ALDH1A1 3129/4885HSD17B10 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.